Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MLNR | O43193 | 1/20 | 0.30 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10326679 | 1.00 | CYP2D6 (0.34) | CYP2D6CYP1A2KDM4ENPC1HPGD | |
| SCHEMBL3229383 | 1.00 | CYP2D6 (0.34) | CYP2D6CYP1A2KDM4ENPC1HPGD | |
| SCHEMBL22260036 | 0.97 | CYP2D6 (0.33) | CYP2D6CYP1A2KDM4ENPC1HPGD | |
| SCHEMBL797872 | 0.97 | CYP2D6 (0.33) | CYP2D6CYP1A2KDM4ENPC1HPGD | |
| SCHEMBL24922624 | 0.97 | CYP2D6 (0.33) | CYP2D6CYP1A2KDM4ENPC1HPGD | |
| SCHEMBL1704716 | 0.92 | — | — | |
| SCHEMBL1705094 | 0.92 | — | — | |
| SCHEMBL164043 | 0.92 | — | — | |
| Methane SCHEMBL28330275 | 0.90 | KDM4E (0.38) | CYP2D6CYP1A2KDM4ENPC1HPGD | |
| Hydrochloric Acid SCHEMBL5241681 | 0.90 | KDM4E (0.42) | CYP2D6CYP1A2KDM4ENPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 352 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110422856-A | Sial type AEI/CHA coexisting molecular sieve method for preparing catalyst and its application being catalyzed in SCR | VALIANT CO LTD | 2019-11-08 | — | — | CN | claimed |
| CN-106745031-B | A kind of high silica alumina ratio SSZ-39 zeolite and its synthesis and application | 中海亚环保材料有限公司 | 2019-05-10 | — | — | CN | claimed |
| CN-109701619-A | SSZ-13/SSZ-39 composite molecular sieves and its synthetic method | 中国石油化工股份有限公司 | 2019-05-03 | — | — | CN | claimed |
| CN-108439426-A | AEI zeolites synthesize | 庄信万丰股份有限公司 | 2018-08-24 | — | — | CN | claimed |
| CN-106745031-A | A kind of zeolites of high silica alumina ratio SSZ 39 and its synthesis and application | 中海亚环保材料有限公司 | 2017-05-31 | — | — | CN | claimed |
| CN-106745057-A | The AEI/MFI eutectics Si-Al molecular sieve and synthetic method of a kind of binder free and application | 中触媒新材料股份有限公司 | 2017-05-31 | — | — | CN | claimed |
| CN-106622359-A | SSZ-39/ZSM-5 composite molecular sieve and synthesis method and application thereof | 中触媒新材料股份有限公司 | 2017-05-10 | — | — | CN | claimed |
| CN-104591204-A | AEI ZEOLITE SYNTHESIS | JOHNSON MATTHEY PLC | 2015-05-06 | — | — | CN | claimed |
| WO-2013177269-A2 | ZIRCONIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION | L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2013-11-28 | — | — | WO | claimed |
| WO-2013177284-A1 | HAFNIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION | L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2013-11-28 | — | — | WO | claimed |
| WO-2013177292-A1 | TITANIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION | L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2013-11-28 | — | — | WO | claimed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| EP-0563345-B1 | NOVEL 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES | MCNEILAB INC (US) | 2002-07-03 | — | — | EP | disclosed |
| CN-1241986-A | A process for preparing zeolites using substituted-piperidinium cations | CHEVRON USA INC (US) | 2000-01-19 | — | — | CN | disclosed |
| US-5569659-A | ANTIPSYCHOTIC AGENT | MCNEILAB, INC. (US) | 1996-10-29 | — | — | US | disclosed |
| EP-0563345-A1 | NOVEL 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES | MCNEILAB, INC. (US) | 1993-10-06 | — | — | EP | disclosed |
| WO-1993004682-A1 | NOVEL 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES | MCNEILAB, INC. (US) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | CYP2D6 3211/4885CYP1A2 2070/4885KDM4E 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.